Compare Sana Biotechnology Inc (SANA) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs United States Natural Gas Fund — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while United States Natural Gas Fund trades at $11.01 (market cap $517.27M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and United States Natural Gas Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and United States Natural Gas Fund for 22 Days on average.
| SANA | UNG | |
|---|---|---|
Market Cap | $836.71M | $517.27M |
Volume | 4,507,444 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $5.92 | $16.90 |
52-Week Low | $2.68 | $9.63 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
UNG trades at $11.01, down 0.18% on the day, with a bullish technical signal from moving averages and neutral oscillators. The fund reported a net income of $65.15 million for 2024, though revenue was $0, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights record U.S. natural gas production and geopolitical tensions affecting energy markets.
The outlook for UNG is mixed, with bullish technicals and solid financials offset by exposure to volatile natural gas prices and high production levels. Investment opportunities lie in potential geopolitical supply disruptions, while risks include weather-dependent demand and sustained high output pressuring prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
